INTRODUCTION
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain, caused by reactivation of JC polyomavirus (JCPyV) previously known as John Cunningham virus. 1 JCPyV, a double-stranded DNA virus, belongs to the polyomavirus family and infects most human subjects (50-90%) during early childhood without causing any clinical symptoms. 2, 3 However, it tends to reactivate and grow in brain glial cells in the presence of immunodeficiency. 4, 5 This may be attributed to HIV, [6] [7] [8] immunosuppressive therapy employed for managing autoimmune diseases (that is, methotrexate, cyclophosphamide, azathioprine and monoclonal antibodies) or for organ rejection following transplantation (mycophenolate). 9, 10 The information regarding the incidence and clinical importance of JCPyV reactivation and risk for PML development in immunosuppressed patients is scarce. In the HIV setting, PML is currently reported in 0.06 cases per 100 patient-years 11 and the data related to these issues in the allogeneic stem cell transplantation (alloSCT) scenario are based on anecdotal case reports only. [12] [13] [14] [15] The objective of the current study was to determine the real-life incidence, clinical course, clinical significance and risk factors for JCPyV reactivation in patients undergoing alloSCT.
PATIENTS AND METHODS
The current study was approved by the institutional review board of the Rambam Health Care Campus (approval # RMB 0097-12). The department database was searched for patients aged 17 or older, treated with a matched alloSCT (either from a sibling, an unrelated donor or cord blood; all fulfilling the criterion of 10/10 HLA match) for a hematological malignancy between 1 January 2008 and 31 December 2011.
Data regarding these subjects, including their demographic characteristics, hematological diseases, treatments applied before allograft, transplant conditioning regimens, post-transplant GvHD and immunosuppression, were recorded.
Frozen DNA samples derived from whole blood, originally drawn at least once a month since hospital admission for transplantation, up to cessation of immunosuppressive therapy or death, for the detection of cytomegalovirus reactivation, were thawed and evaluated for JCPyV reactivation using the quantitative JCPyV PCR analysis.
Patients were excluded from the analysis if they had no consecutive stored DNA samples obtained post alloSCT. The clinical course of patients who developed JCPyV reactivation was recorded, focusing on neurological and infection-related complications and immunosuppressive therapy employed.
PCR protocol for JCPyV DNA detection
The stored total nucleic acid samples originally taken as part of the routine detection of CMV-PCR surveillance strategy were evaluated for occult JCPyV reactivation. Total DNA was extracted from patients' whole blood samples (200 μL per sample), using the Magna Pure LC 2.0 apparatus and Magna Pure LC total Nucleic Acid Isolation Kit Reagents (Roche Diagnostics, Germany) according to the manufacturer's instructions (elution volume 100 μL). TaqMan Real Time PCR was performed according to Ryschkewitsch et al. 16 The primers and probe were derived from the nucleotide sequences of the N terminus of the T antigen of JCPyV: 5′-GAG TGTTGGGATCCTGTGTTTT-3′ (FW), 5′-AGAAGTGGGAT GAAGACCTGTTT-3′ (RV) and Probe 5′FAM-TCATCACTGGCAAA CATTTCTTCATGGC-BHQ-1-3′.
The PCR was performed in a total volume of 25 μL containing Absolute Blue QPCR mix (Thermo Scientific, UK) in the presence of 10 μL target DNA, 300 nM of each primer, and 200 nM of the probe. PCR was performed on the rotor gene 3000 or 6000 instrument (Corbett Research/Qiagen, Hilden, Germany) under the following conditions: 15 min at 95°C, 45 cycles of 15 s at 95°C and 60 s at 60°C. For quantitative result analysis, an average standard curve was constructed using quantified JCPyV DNA (Advanced Biotechnology Industry). Results were reported as the number of JCPyV genome copies per 1 mL of blood. The lowest viral load that can be detected by the assay used at our laboratory is 100 copies/mL. However, the limit of detection, defining the copy number which ensures a 100% detection rate, is 500 copies/mL. The specificity of this assay is 100%.
Definitions
JCPyV reactivation was defined as transient if a single peripheral blood (PB) sample was JCPyV positive. JCPyV reactivation was defined as persistent when at least two PB samples were JCPyV positive.
Follow-up time: was defined as time from alloSCT to the identification of the first JCPyV-positive sample in PB, or up to 18 months or death (whichever came first), if all samples were negative.
Disease categories: lymphoproliferative diseases (LPD) included Hodgkin lymphoma, non-Hodgkin lymphoma, CLL and multiple myeloma.
Conditioning regimen: according to the definition established by the European Group for Blood and Marrow Transplantation, myeloablative conditioning regimens included: (1) cyclophosphamide plus TBI, (2) cyclophosphamide plus busulphan, with or without other cytotoxic agents and/or antithymocyte globulin or alemtuzumab, and (3) carmustine, etoposide, cytarabine and melphalan or carmustine, etoposide, cytarabine and cyclophosphamide. Reduced-intensity conditioning protocols included fludarabine plus one or two alkylating agents, or a low-dose TBI (2-4 Gy), with or without ATG or alemtuzumab. Alkylating agents included busulphan, melphalan, cyclophosphamide or thiotepa.
Donor type: a fully matched sibling or a matched unrelated donor were determined by high-resolution testing at HLA-A, -B, -C and -DRB1, with or without DQB1 level (8/8 or 10/10). Mismatched unrelated donors were excluded.
GvHD: was defined according to accepted criteria. Chronic GvHD was evaluated in patients who engrafted, survived 4100 days and whose disease did not progress; therefore, they did not receive either donor lymphocyte infusion or relapse-related therapy. 17 Overall survival: was defined as the time from transplant to death from any cause, with surviving patients censored as alive at the last follow-up. Both recurrence and progression were defined as disease progression, with a non-relapse death considered a competing event. Non-relapse mortality was defined as death due to any cause, which occurred without previous disease progression after transplant.
Statistical analysis
Comparison between patient group characteristics was done using the chisquare test.
The bivariate Cox regression analysis was used to identify factors affecting JCPyV reactivation, at least once (transient or persistent) and twice or more (persistent only). Risk factors with P-value o0.1 were evaluated using the multivariate Cox regression analysis.
The JCPyV reactivation-free survival and overall survival were calculated using Kaplan-Meier analysis.
The median nonparametric test was used to identify differences between patients with persistent and transient reactivation.
P-value o0.05 was defined as statistically significant. Data analysis was conducted using the SPSS version 18. Table 1 .
RESULTS

Patient characteristics
The most common indication for transplant was acute leukemia (AML, ALL), followed by LPD, myelodysplastic syndrome and myeloproliferative disorders.
The median time from the diagnosis to alloSCT was 7.3 months (range 1.2-181.1), while the median number of prior therapies approached 2 (range 0-7). Thirty patients (18.3%) received rituximab 0.2-85 months (median 2.0 months) before transplant, including 16 (53%) who were heavily pretreated (⩾10 rituximab doses). Data regarding the donor source, conditioning regimens before stem cell infusion and GvHD occurrence are detailed in Table 1 .
One hundred and sixty one patients (98%) received cyclosporine as part of their immunosuppressive regimen during the postalloSCT follow-up (Table 1) . Only three patients did not receive cyclosporine-one received steroids alone, one tacrolimus alone and one received three drugs (steroids, tacrolimus and MMF). The causes of death were disease relapse (n = 2), infection (n = 6), including bacterial (n = 4), invasive fungal (n = 1) and viral ones (n = 1), GvHD (n = 2) and multiple organ failure (n = 2).
Clinical course of patients experiencing persistent JCPyV reactivation Twenty patients developed persistent JCPyV reactivation, including 13 who had at least three positive consecutive tests. The median time from alloSCT to initial reactivation was 49 days (range 7-959). Seventeen patients (85%) were continuously treated with immunosuppressive therapy due to acute and/or chronic GvHD, lasting for 1 year and/or up to death. Twelve patients in the persistent reactivation group (60%) developed neurological complications. Seven patients (35%) presenting with 'PMLsuspicious symptoms' underwent a diagnostic lumbar puncture for JCPyV, which was confirmed to be positive in two patients only, and in these two patients the brain MRI result was consistent with the PML diagnosis. At PML diagnosis, JCPyV DNA levels of these patients were 870 and 2 500 000 copies/mL in the PB, and 4000 and over 1 000 000 copies/mL in the cerebrospinal fluid, respectively. In another two patients, an alternative diagnosis was made, that is, cerebral post-transplant lymphoproliferative disease (n = 1) and invasive fungal sinusitis with intracranial involvement (n = 1). In three additional patients the neurological symptoms resolved without a specific diagnosis (both lumbar puncture and imaging were negative). In the remaining five patients lumbar puncture was not performed: two were diagnosed with steroidinduced symptoms (confusion, n = 1; myopathy, n = 1), one had hepatic encephalopathy, and in two others the symptoms resolved without a specific diagnosis. Of note, two of the patients with persistent reactivation (experiencing no neurological symptoms) developed hemorrhagic cystitis.
Fifteen of those who developed persistent reactivation (75%) died within a median period of 126 days after appearance of the first evidence for JCPyV reactivation (range 11-435 days). The causes of death were disease relapse (n = 3), infections (n = 10), including PML (n = 1), invasive fungal infection (n = 3) and bacterial infections (n = 6), post-transplant lymphoproliferative disorder (n = 1) and GvHD (n = 1). Abbreviations: ALL = acute lymphocytic leukemia; AML = acute myeloid leukemia; ATG = anti-thymocyte globulin; autoSCT = autologous stem cell transplantation; BPL = biphenotypic leukemia; CB = cord blood; CLL = chronic lymphocytic leukemia; CML = chronic myeloid leukemia; GvHD = graft-versus-host disease; LPD = lymphoproliferative disease (including Hodgkin and non-Hodgkin lymphoma); MDS = myelodysplastic syndrome; MM = multiple myeloma; MMF = mycophenolate mofetil; MMR = mismatched related donor; MPD = myeloproliferative disease; MRD = matched related donor; MUD = matched unrelated donor; SCT = stem cell transplantation. Risk factors for JCPyV reactivation All 164 patients were included in the analysis. Age greater than 40 years at the time of SCT, diagnosis of LPD and administration of fludarabine or melphalan as part of the conditioning protocol were found to be associated with an increased risk for JCPyV reactivation in a bivariate analysis. Table 2 presents the results of the bivariate analysis of risk factors for JCPyV reactivation. The risk of JCPyV reactivation was found to significantly increase with age, approaching 27% in patients aged 41-60 years and 36% in patients older than 60 years, which is much higher than the percentage reported in patients younger than 30 years, in whom that risk was only 7% (Table 2; Figure 2) .
Patients transplanted for LPD had a 2.2 times higher risk of JCPyV reactivation than individuals transplanted for other hematological malignancies. Intensified rituximab treatment, including at least 10 doses, led to a nonsignificant trend for an increased risk ( Table 2 ). The risk of JCPyV reactivation in patients receiving fludarabine or melphalan as part of their pre-SCT conditioning regimen was 2.4 and 2.0 times greater than that recorded in patients receiving a 'non-fludarabine' or 'nonmelphalan' conditioning regimen, respectively. In consensus with this finding, a reduced-intensity conditioning regimen (which contained fludarabine and melphalan in most cases) was demonstrated to be associated with an increased risk of JCPyV reactivation. In addition, the male gender seemed to be associated with a higher risk of JCPyV reactivation (30% vs 17%; P = 0.086), although the difference was not statistically significant (Table 2) .
Multivariate analysis (Table 3) showed age older than 40 years (P = 0.030) to be the only statistically significant risk factor predicting JCPyV reactivation.
Risk factors for persistent JCPyV reactivation Additional analysis was employed to identify the risk factors for persistent reactivation only, comparing the combined group of patients with transient reactivation and those who had never experienced JCPyV reactivation (n = 124) with individuals who developed persistent reactivation (n = 20). A previous use of rituximab, previous alloSCT, administration of MMF and concurrent use of 43 immunosuppressive agents were found to predict persistent JCPyV reactivation in a bivariate analysis (Table 4) . Multivariate analysis was not applicable due to the low number of patients in the group with persistent JCPyV reactivation.
DISCUSSION
Reactivation of JCPyV in the urinary tract due to immunodeficiency may occasionally result in virus migration to the PB and transition into the brain, [18] [19] [20] [21] eventually leading to the development of neurological sequelae and death. 4, 22 Currently available pharmacotherapeutic agents are usually ineffective at the time of 'overt PML' 8 and patients die within several months of diagnosis. 23, 24 The restoration of immune function, achieved either by withdrawal of immunosuppressive agents in transplanted patients or by administration of highly active antiretroviral therapy in HIV patients, appears to be the most effective approach, [25] [26] [27] although often insufficient in the presence of an overwhelming, progressive infection.
AlloSCT is associated with marked immunosuppression, attributed to the combination of immunosuppressive conditioning regimens, which significantly impair the recipient's immune system, 28 and the development of post-transplant GvHD, requiring an intensive administration of immunosuppressive agents. 29 Nevertheless, in contrast to patients undergoing solid organ transplantation, who require immunosuppressive therapy during their entire life, patients undergoing alloSCT can often discontinue immunosuppressive agents within several months post transplant, which results in gradual immune reconstitution and may at least partly explain the low reported rate of PML in patients undergoing alloSCT. 30 Consequently, the elimination of a hematological malignancy achieved through allograft may also contribute to immune restoration and JCPyV clearance.
The growing number of allografts being performed, reflecting the employment of reduced intensity regimens (enabling allografts in older subjects) 31 with a more intensive immunosuppressive therapy, as well as the elevation in the rate of chronic GvHD, and the increased availability of matched unrelated donors, may result in a more frequent occurrence of this complication.
To the best of our knowledge, the current study is the largest ever performed in a consecutive cohort of patients treated with an alloSCT, vigorously assessing the occurrence of JCPyV reactivation and evaluating its incidence and clinical significance.
A quarter of patients undergoing allograft experience at least a transient reactivation of JCPyV in PB, a phenomenon previously shown to reflect immune impairment, rather than an anecdotal finding in healthy subjects. 32 It should be noted that at least in some cases, the observed JCPyV DNA load may reflect reactivation of a donor's JCPyV rather than that of a patient's. 3, 33 Multivariate analysis found older age to be the most important risk factor for developing JCPyV reactivation, a finding which is in agreement with a recent study reporting a decreased cellular response against JCPyV, with an increased risk for JCPyV reactivation in older patients. 34 The diagnosis of a lymphoid disease and the administration of fludarabine-or melphalan-based reduced intensity regimens appeared to be significant risk factors in the univariate analysis, reflecting the fact that these conditioning protocols were commonly employed in older patients and those undergoing allograft for LPD.
JCPyV reactivation, though relatively frequent, appeared to be persistent in 12% of patients only, resulting in PML development in 10% of these individuals. However, no cases of PML evolution were observed among the patients in whom JCPyV reactivation was not persistent. Moreover, although the number of patients who eventually developed PML in this study was low, most individuals who experienced persistent JCPyV reactivation died of unrelated infections shortly afterwards, not having 'enough time' to develop PML. While rituximab therapy by itself was not associated with a significant increase in the risk for JCPyV reactivation, a high cumulative dose (compatible with 410 doses) of the drug was found to elevate the risk of persistent reactivation. These data are consistent with prior reports, suggesting a modest increase in PML development in patients receiving this monoclonal antibody for autoimmune disorders. 10 However, differences in the underlying diseases and the fact that JCPyV reactivation results in PML development only in a minority of cases, should be considered when discussing the real impact of rituximab exposure on JCPyV reactivation and progression. Additionally, a second transplant after a prior alloSCT and concurrent employment of 43 immunosuppressive agents were associated with an increased risk of persistent rather than transient reactivation. This finding emphasizes the significant connection between profound, persistent immunodeficiency and JCPyV reactivation. 35 Unfortunately, fresh blood samples, allowing for an assessment of anti-JCPyV immune response and its potential correlation with JCPyV DNA load were unavailable in our study; therefore, the JCPyV analysis was performed on frozen samples, initially collected for CMV detection.
Nevertheless, data from the prospective study reported by Tan et al. suggest JCPyV viremia to be associated with a weaker cellular immune response to JCPyV, 34 an observation which might at least partly explain why only a minority of patients develop persistent reactivation.
In the current study, the JCPyV DNA load was revealed in 40 (24%) of 164 patients; however, only 20 of them had persistent reactivation accompanied by a gradual increase in JCPyV copy number. Two of these patients eventually developed PML. 36 In one patient, cessation of immunosuppression resulted in JCPyV disappearance and PML resolution. In the other patient, an attempt to decrease immunosuppression resulted in a transient decrease in the JCPyV copy number; however, resumption of immunosuppression due to GvHD aggravation was followed by an increase in the JCPyV DNA load and death. The rare occurrence of PML, even in allografted patients with JCPyV DNA load, is consistent with the findings of a recent study in HIV patients where the JCPyV DNA load was not predictive of PML development. 37 Early detection of gradually growing persistent JCPyV DNA load may require a reduction in immunosuppressive therapy in suitable cases, and/or early administration of potentially active anti-JCPyV agents. The latter, though ineffective in overt PML, could be used in combination with partial reduction of immunosuppression to eradicate JCPyV at an early stage, thereby preventing PML development.
In summary, this study confirms that PML is a rare event in the alloSCT setting. When it does occur it is a life-threatening complication. Therefore, a preemptive approach to the management of high-risk patients, namely older adults, those diagnosed with lymphoid malignancies and/or heavily treated with immunosuppressive agents, may allow for early detection and employment of a PML preventive treatment. While the current study has failed to determine the exact JCPyV load that leads to PML evolution, persistent reactivation is associated with higher JCPyV levels and may predict a higher general mortality and an increased risk for PML development. Further studies are warranted to clarify the pathophysiology of PML development and the applicability of the proposed preventive strategy, including quantitative PCR tests in PB and the adoption of routine cognitive assessment and MRI imaging in high-risk patients.
